Vaccinia Virus Vectors with an Inactivated Gamma Interferon Receptor Homolog Gene (B8R) Are Attenuated In Vivo Without a Concomitant Reduction in Immunogenicity

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2000 Dec 19

PMID 11119568

Citations 34

Authors

P H Verardi

L A Jones

F H Aziz

S Ahmad

T D Yilma

Affiliations

Soon will be listed here.

Abstract

The vaccinia virus (VV) B8R gene encodes a secreted protein with homology to the gamma interferon (IFN-gamma) receptor. In vitro, the B8R protein binds to and neutralizes the antiviral activity of several species of IFN-gamma, including human and rat IFN-gamma; it does not, however, bind significantly to murine IFN-gamma. Here we report on the construction and characterization of recombinant VVs (rVVs) lacking the B8R gene. While the deletion of this gene had no effect on virus replication in vitro, rVVs lacking the B8R gene were attenuated for mice. There was a significant decrease in weight loss and mortality in normal mice, and nude mice survived significantly longer than did controls inoculated with parental virus. This is a surprising result considering the minimal binding of the B8R protein to murine IFN-gamma and its failure to block the antiviral activity of this cytokine in vitro. Such reduction in virulence could not be determined in rats, since they are considerably more resistant to VV infection than are mice. Finally, deletion of the B8R gene had no detectable effects on humoral immune responses. Mice and rats vaccinated with the rVVs showed identical humoral responses to both homologous and heterologous genes expressed by VV. This study demonstrates that the deletion of the VV B8R gene leads to enhanced safety without a concomitant reduction in immunogenicity.

Citing Articles

Oncolytic vaccinia virus and cancer immunotherapy.

Xu L, Sun H, Lemoine N, Xuan Y, Wang P Front Immunol. 2024; 14:1324744.

PMID: 38283361 PMC: 10811104. DOI: 10.3389/fimmu.2023.1324744.

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

Boulton S, Poutou J, Gill R, Alluqmani N, He X, Singaravelu R Mol Ther Methods Clin Dev. 2023; 31:101110.

PMID: 37822719 PMC: 10562195. DOI: 10.1016/j.omtm.2023.101110.

CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.

Whelan J, Singaravelu R, Wang F, Pelin A, Tamming L, Pugliese G Front Immunol. 2023; 13:1050250.

PMID: 36713447 PMC: 9880309. DOI: 10.3389/fimmu.2022.1050250.

Replication-inducible vaccinia virus vectors with enhanced safety in vivo.

OConnell C, Jasperse B, Hagen C, Titong A, Verardi P PLoS One. 2020; 15(4):e0230711.

PMID: 32240193 PMC: 7117657. DOI: 10.1371/journal.pone.0230711.

A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses.

Prow N, Liu L, Nakayama E, Cooper T, Yan K, Eldi P Nat Commun. 2018; 9(1):1230.

PMID: 29581442 PMC: 5964325. DOI: 10.1038/s41467-018-03662-6.

References

Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K . Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J Virol. 1999; 73(6):5196-200. PMC: 112570. DOI: 10.1128/JVI.73.6.5196-5200.1999. View

Price N, Tscharke D, Hollinshead M, Smith G . Vaccinia virus gene B7R encodes an 18-kDa protein that is resident in the endoplasmic reticulum and affects virus virulence. Virology. 2000; 267(1):65-79. DOI: 10.1006/viro.1999.0116. View

Ourmanov I, Brown C, Moss B, Carroll M, Wyatt L, Pletneva L . Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol. 2000; 74(6):2740-51. PMC: 111764. DOI: 10.1128/jvi.74.6.2740-2751.2000. View

Jones L, Ahmad S, Chan K, Verardi P, Morton W, Grant R . Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines. J Med Primatol. 2000; 29(3-4):231-9. DOI: 10.1034/j.1600-0684.2000.290316.x. View

Spriggs M, Hruby D, Maliszewski C, Pickup D, Sims J, Buller R . Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell. 1992; 71(1):145-52. DOI: 10.1016/0092-8674(92)90273-f. View

Alcami A, Smith G . A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 1992; 71(1):153-67. DOI: 10.1016/0092-8674(92)90274-g. View

Upton C, Mossman K, McFadden G . Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science. 1992; 258(5086):1369-72. DOI: 10.1126/science.1455233. View

Giavedoni L, Jones L, Gardner M, GIBSON H, Ng C, Barr P . Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A. 1992; 89(8):3409-13. PMC: 48877. DOI: 10.1073/pnas.89.8.3409. View

Cooney E, Collier A, Greenberg P, Coombs R, Zarling J, Arditti D . Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991; 337(8741):567-72. DOI: 10.1016/0140-6736(91)91636-9. View

10.

Baxby D . Safety of recombinant vaccinia vaccines. Lancet. 1991; 337(8746):913. DOI: 10.1016/0140-6736(91)90241-g. View

11.

Lai A, Chu Y . A rapid method for screening vaccinia virus recombinants. Biotechniques. 1991; 10(5):564-5. View

12.

Isaacs S, Kotwal G, Moss B . Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A. 1992; 89(2):628-32. PMC: 48292. DOI: 10.1073/pnas.89.2.628. View

13.

Howard S, Chan Y, Smith G . Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology. 1991; 180(2):633-47. DOI: 10.1016/0042-6822(91)90077-o. View

14.

Giavedoni L, Jones L, Mebus C, Yilma T . A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci U S A. 1991; 88(18):8011-5. PMC: 52435. DOI: 10.1073/pnas.88.18.8011. View

15.

Ada G . Vaccine development. Real and imagined dangers. Nature. 1991; 349(6308):369. DOI: 10.1038/349369a0. View

16.

Smith G, Chan Y, Howard S . Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J Gen Virol. 1991; 72 ( Pt 6):1349-76. DOI: 10.1099/0022-1317-72-6-1349. View

17.

King N, Woodhams C, Ramshaw I . Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol. 1990; 20(1):157-61. DOI: 10.1002/eji.1830200123. View

18.

Macgregor G, Nolan G, Fiering S, Roederer M, Herzenberg L . Use of Escherichiu coli (E. coli) lacZ (β-Galactosidase) as a Reporter Gene. Methods Mol Biol. 2011; 7:217-35. DOI: 10.1385/0-89603-178-0:217. View

19.

Zhou J, Crawford L, McLean L, Sun X, Stanley M, Almond N . Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J Gen Virol. 1990; 71 ( Pt 9):2185-90. DOI: 10.1099/0022-1317-71-9-2185. View

20.

Williamson J, Reith R, Jeffrey L, Arrand J, Mackett M . Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol. 1990; 71 ( Pt 11):2761-7. DOI: 10.1099/0022-1317-71-11-2761. View